General Information of Drug Combination (ID: DCREWE5)

Drug Combination Name
Cabazitaxel Vincristine
Indication
Disease Entry Status REF
Plasma cell myeloma Investigative [1]
Component Drugs Cabazitaxel   DMPAZHC Vincristine   DMINOX3
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: RPMI-8226
Zero Interaction Potency (ZIP) Score: 8.57
Bliss Independence Score: 7.28
Loewe Additivity Score: 3.57
LHighest Single Agent (HSA) Score: 7.87

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Cabazitaxel
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Metastatic prostate carcinoma N.A. Investigative [3]
Cabazitaxel Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [6]
------------------------------------------------------------------------------------
Cabazitaxel Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [7]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Cabazitaxel Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Forkhead box protein O3 (FOXO3) OTHXQG4P FOXO3_HUMAN Affects Expression [8]
Proline-rich AKT1 substrate 1 (AKT1S1) OT4JHN4Y AKTS1_HUMAN Decreases Expression [8]
------------------------------------------------------------------------------------
Indication(s) of Vincristine
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [4]
Adult kidney Wilms tumor N.A. Approved [5]
Beckwith-Wiedemann syndrome N.A. Approved [5]
Burkitt lymphoma N.A. Approved [5]
Central nervous system neoplasm N.A. Approved [5]
Childhood acute lymphoblastic leukemia N.A. Approved [5]
Childhood kidney Wilms tumor N.A. Approved [5]
Hamartoma N.A. Approved [5]
Kidney neoplasm N.A. Approved [5]
Leukemia N.A. Approved [5]
MALT lymphoma N.A. Approved [5]
Nodal marginal zone lymphoma 2A85.0 Approved [5]
Plasma cell myeloma 2A83.1 Approved [5]
Primitive neuroectodermal tumor N.A. Approved [5]
Splenic marginal zone lymphoma N.A. Approved [5]
Testicular lymphoma N.A. Approved [5]
Wilms tumor N.A. Approved [5]
Classic Hodgkin lymphoma N.A. Investigative [5]
Follicular lymphoma 2A80 Investigative [5]
Neuroblastoma 2D11.2 Investigative [5]
Vincristine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [9]
------------------------------------------------------------------------------------
Vincristine Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [10]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [11]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [13]
------------------------------------------------------------------------------------
Vincristine Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [14]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [14]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [15]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DC0X5FB DU-145 Investigative [1]
Adenocarcinoma DCHR3JP OVCAR3 Investigative [1]
Adenocarcinoma DCWN328 HCT-15 Investigative [1]
Adenocarcinoma DCRT3BG HCC-2998 Investigative [1]
Adenocarcinoma DCV5J7A HCT116 Investigative [1]
Adenocarcinoma DCLJSXB HT29 Investigative [1]
Adult acute myeloid leukemia DCT8VKH HL-60(TB) Investigative [1]
Adult T acute lymphoblastic leukemia DCKJ4NN MOLT-4 Investigative [1]
Anaplastic large cell lymphoma DC35GTA SR Investigative [1]
Childhood T acute lymphoblastic leukemia DCCZ7OK CCRF-CEM Investigative [1]
Clear cell renal cell carcinoma DC6FJ7Q 786-0 Investigative [1]
Glioma DCM8W84 SF-539 Investigative [1]
Glioma DCNP0PM SF-295 Investigative [1]
High grade ovarian serous adenocarcinoma DC9ZEF7 OVCAR-4 Investigative [1]
Large cell lung carcinoma DCC7BHU NCI-H460 Investigative [1]
Lung adenocarcinoma DCAT2EX NCI-H522 Investigative [1]
Malignant melanoma DCVX2JS UACC62 Investigative [1]
Minimally invasive lung adenocarcinoma DCFQXR9 NCI-H322M Investigative [1]
Ovarian serous cystadenocarcinoma DCR36OI SK-OV-3 Investigative [1]
Prostate carcinoma DCP63RT PC-3 Investigative [1]
Renal cell carcinoma DCPGT88 SN12C Investigative [1]
Breast adenocarcinoma DC414L0 MDA-MB-468 Investigative [16]
Carcinoma DC8MV6Z RXF 393 Investigative [16]
Carcinoma DC84J5F MCF7 Investigative [16]
Invasive ductal carcinoma DCF7AH2 HS 578T Investigative [16]
Invasive ductal carcinoma DCUVW85 BT-549 Investigative [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 26 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6798).
3 Cabazitaxel FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6785).
5 Vincristine FDA Label
6 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
7 DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
8 The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling. Toxicol Appl Pharmacol. 2020 Aug 15;401:115091. doi: 10.1016/j.taap.2020.115091. Epub 2020 Jun 7.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31.
11 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
12 L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18.
13 Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
14 Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
15 Drug Interactions Flockhart Table
16 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.